How many drugs treat Erdheim-Chester Disease?

Drug Landscape tracks 2 marketed treatments for Erdheim-Chester Disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/erdheim-chester-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Erdheim-Chester Disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Erdheim-Chester Disease (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Erdheim-Chester Disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Zelboraf	vemurafenib	Hoffmann La Roche	Kinase Inhibitor [EPC]	Serine/threonine-protein kinase B-raf		2011-01-01
Zelboraf	Zelboraf	Hoffmann-La Roche		Aspartyl/asparaginyl beta-hydroxylase, Ferrochelatase, mitochondrial, Dual specificity mitogen-activated protein kinase kinase 5

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Hoffmann La Roche · 1 drug in Erdheim-Chester Disease
Hoffmann-La Roche · 1 drug in Erdheim-Chester Disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Erdheim-Chester Disease:

Cite this brief

Drug Landscape (2026). Erdheim-Chester Disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/erdheim-chester-disease. Accessed 2026-06-10.

Erdheim-Chester Disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing